Analysed APPILI THERAPEUTICS INC-CL A (APLIF:OTCMKTS) News Sources
Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
18-02-2026
yahoo.com
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
12-02-2026
yahoo.com
Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
18-12-2025
yahoo.com
The Lundquist Institute and its start-up company Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 Million Competitive Contract from NIH/NIAID
15-12-2025
yahoo.com
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
13-11-2025
yahoo.com
The Lundquist Institute and Its Start-Up Company Vitalex Biosciences Announce Strategic Advancement of Second-Generation Fungal Vaccine VXV-01 Through Phase 1 Trials Under $40 Million Competitive Contract From NIH/NIAID
12-11-2025
yahoo.com
What is the current price of APPILI THERAPEUTICS INC-CL A (APLIF:OTCMKTS)?
The current price of APPILI THERAPEUTICS INC-CL A (APLIF:OTCMKTS) is $0.0126.
APPILI THERAPEUTICS INC-CL A (APLIF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of APPILI THERAPEUTICS INC-CL A (APLIF:OTCMKTS) since the previous trading day is $-0.0004.
APPILI THERAPEUTICS INC-CL A (APLIF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of APPILI THERAPEUTICS INC-CL A (APLIF:OTCMKTS) since the previous trading day is -3.0769%.
What is the most recent average sentiment score for APPILI THERAPEUTICS INC-CL A (APLIF:OTCMKTS)?
The most recent average sentiment score for APPILI THERAPEUTICS INC-CL A (APLIF:OTCMKTS) is 81 out of 100.
What is the most recent average sentiment for APPILI THERAPEUTICS INC-CL A (APLIF:OTCMKTS)?
The most recent sentiment for APPILI THERAPEUTICS INC-CL A (APLIF:OTCMKTS) is .
SEC-8K** Filing Available For APPILI THERAPEUTICS INC-CL A (APLIF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.